Literature DB >> 10861060

The HTLV-I tax protein transcriptionally modulates OX40 antigen expression.

R Pankow1, H Dürkop, U Latza, H Krause, U Kunzendorf, T Pohl, S Bulfone-Paus.   

Abstract

OX40 is a member of the TNF receptor family, expressed on activated T cells. It is the only costimulatory T cell molecule known to be specifically up-regulated in human T cell leukemia virus type-I (HTLV-I)-producing cells. In a T cell line, OX40 surface expression was shown to be induced by HTLV-I Tax alone. To understand molecular mechanisms of OX40 gene regulation and modulation by HTLV-I Tax, we have cloned the human OX40 gene and analyzed its 5'-flanking region. By reporter gene analysis with progressive 5' deletions from nucleotides -1259 to -64, we have defined a 157-bp DNA fragment as a minimal promoter for constitutive expression. In addition, we show that in the OX40+ cell line, Co, Tax is able to further increase OX40 surface expression. Up-regulation of OX40 promoter activity by Tax requires two upstream NF-kappaB sites, which are not active in the constitutive OX40 expression. Their deletion abrogates Tax responsiveness in reporter gene analysis. The site-directed mutagenesis of each NF-kappaB site demonstrates that cooperative NF-kappaB binding is a prerequisite for Tax-directed activity as neither site alone is sufficient for a full Tax responsiveness of the OX40 promoter. Upon Tax expression, both sites bind p65 and c-Rel. These data provide new insight into the direct regulation of OX40 by Tax and add to our understanding of the possible role of the OX40/OX40 ligand system in the proliferation of HTLV-I+ T cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861060     DOI: 10.4049/jimmunol.165.1.263

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  OX40 stimulation by gp34/OX40 ligand enhances productive human immunodeficiency virus type 1 infection.

Authors:  Y Takahashi; Y Tanaka; A Yamashita; Y Koyanagi; M Nakamura; N Yamamoto
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 2.  OX40:OX40L axis: emerging targets for improving poxvirus-based CD8(+) T-cell vaccines against respiratory viruses.

Authors:  John Goulding; Vikas Tahiliani; Shahram Salek-Ardakani
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

3.  Increased expression of OX40 is associated with progressive disease in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis.

Authors:  Mineki Saito; Reiko Tanaka; Shiho Arishima; Toshio Matsuzaki; Satoshi Ishihara; Takashi Tokashiki; Yusuke Ohya; Hiroshi Takashima; Fujio Umehara; Shuji Izumo; Yuetsu Tanaka
Journal:  Retrovirology       Date:  2013-05-07       Impact factor: 4.602

Review 4.  Cell surface markers in HTLV-1 pathogenesis.

Authors:  Andrea K Kress; Ralph Grassmann; Bernhard Fleckenstein
Journal:  Viruses       Date:  2011-08-16       Impact factor: 5.048

Review 5.  Human T-cell lymphotropic virus: a model of NF-κB-associated tumorigenesis.

Authors:  Zhaoxia Qu; Gutian Xiao
Journal:  Viruses       Date:  2011-06       Impact factor: 5.048

6.  Development of ultra-super sensitive immunohistochemistry and its application to the etiological study of adult T-cell leukemia/lymphoma.

Authors:  Kazuhisa Hasui; Jia Wang; Yuetsu Tanaka; Shuji Izumo; Yoshito Eizuru; Takami Matsuyama
Journal:  Acta Histochem Cytochem       Date:  2012-04-21       Impact factor: 1.938

Review 7.  Distinct functions of HTLV-1 Tax1 from HTLV-2 Tax2 contribute key roles to viral pathogenesis.

Authors:  Masaya Higuchi; Masahiro Fujii
Journal:  Retrovirology       Date:  2009-12-17       Impact factor: 4.602

8.  Reduction of human T-cell leukemia virus type 1 (HTLV-1) proviral loads in rats orally infected with HTLV-1 by reimmunization with HTLV-1-infected cells.

Authors:  Kazuya Komori; Atsuhiko Hasegawa; Kiyoshi Kurihara; Takayuki Honda; Hiroo Yokozeki; Takao Masuda; Mari Kannagi
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.